Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes

BACKGROUND: The cytokine IL-17 is a key player in autoimmune processes, while the cytokine IL-6 is responsible for the chronification of inflammation. However, their roles in type 1 diabetes development are still unknown. METHODS: Therefore, therapies for 5 days with anti-IL-17A or anti-IL-6 in comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Jörns, Anne, Ishikawa, Daichi, Teraoku, Hiroki, Yoshimoto, Toshiaki, Wedekind, Dirk, Lenzen, Sigurd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047363/
https://www.ncbi.nlm.nih.gov/pubmed/32106855
http://dx.doi.org/10.1186/s12916-020-1503-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047363/
https://www.ncbi.nlm.nih.gov/pubmed/32106855
http://dx.doi.org/10.1186/s12916-020-1503-6

Ejemplares similares